NCT06212297View on ClinicalTrials.gov

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

February 6, 2025

Study Completion Date

March 31, 2029

Conditions
Inherited Retinal Dystrophy
Interventions
GENETIC

LX101

Subretinal administration of LX101 to the contralateral, previously uninjected eye

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Innostellar Biotherapeutics Co.,Ltd

INDUSTRY